Your browser doesn't support javascript.
loading
Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study.
Mukherjee, Sarbajit; Ibrahimi, Sami; Machiorlatti, Michael; Roman, Darwin; Saleem, Rabia; Hassan, Ayesha; Baxley, Allison; Vesely, Sara; Aljumaily, Raid.
Afiliação
  • Mukherjee S; Division of Hematology-Oncology, Department of Internal Medicine, University of Oklahoma, Oklahoma City, Oklahoma.
  • Ibrahimi S; Division of Hematology-Oncology, Department of Internal Medicine, University of Oklahoma, Oklahoma City, Oklahoma.
  • Machiorlatti M; Department of Biostatistics and Epidemiology, University of Oklahoma, Oklahoma City, Oklahoma.
  • Roman D; Department of Internal Medicine, University of Oklahoma, Oklahoma City, Oklahoma.
  • Saleem R; Department of Internal Medicine, University of Oklahoma, Oklahoma City, Oklahoma.
  • Hassan A; Department of Internal Medicine, University of Oklahoma, Oklahoma City, Oklahoma.
  • Baxley A; Department of Clinical Pharmacy Services, University of Oklahoma, Oklahoma City, Oklahoma.
  • Vesely S; Department of Biostatisctics and Epidemiology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
  • Aljumaily R; Division of Hematology-Oncology, Department of Internal Medicine, University of Oklahoma, Oklahoma City, Oklahoma.
Am J Ther ; 25(6): e767-e768, 2018.
Article em En | MEDLINE | ID: mdl-29746291
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article